A due-diligence checklist for in-vitro research procurement under UAE MoHAP Circular 17/2022. Retatrutide is investigational and not approved for human or veterinary use. Use this page to verify suppliers, then jump to the Retatrutide 30mg Pen, the Retatrutide 20mg Pen COA, or the full Retatrutide UAE pricing and delivery reference for current tiers and dispatch timing.
Quick answer: The current Dubai research route is a Janoshik-verified prefilled pen supply, not a pharmacy listing. The 30mg format starts at AED 1,800, drops to AED 1,500 per pen at the 5+ tier, and ships same day in Dubai when confirmed by 4 PM. If you want trials, dosing, and approval routing, use the Retatrutide Research Hub. For the commercial overview across the Emirates, use Retatrutide UAE.
Retatrutide is investigational and labelled For Research Use Only under UAE MoHAP Circular 17/2022. It is not approved for human or veterinary use anywhere in the GCC. Treat supplier selection in Dubai as a verification workflow: confirm a batch-linked HPLC COA, sanity-check the price against the purity claimed, choose a format appropriate for the protocol, and confirm cold-chain handling. After those checks, the Dubai price and delivery reference covers current tiers, dispatch timing, and proof links.
This page is for due diligence first. If a supplier passes the screen below, continue to the Dubai price and delivery guide for live tiers, timing, and order steps.
Retatrutide (LY-3437943) is a triple-agonist peptide developed by Eli Lilly that simultaneously activates three metabolic receptors: GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and GCGR (glucagon receptor). This three-receptor mechanism distinguishes it from single-agonist compounds like semaglutide and dual-agonist compounds like tirzepatide.
In a Phase 2 trial published in the New England Journal of Medicine, retatrutide demonstrated a 24.2% mean body weight reduction at the highest dose over 48 weeks. Eli Lilly’s Phase 3 TRIUMPH clinical trial programme is still generating additional readouts, and Lilly has not publicly announced an NDA filing date as of April 22, 2026. For a detailed regulatory timeline, see our retatrutide approval status tracker.
All retatrutide materials supplied by Remy Peptides are strictly for in-vitro laboratory research and are not intended for human or veterinary administration.
Two prefilled pen formats are currently in active Dubai supply. The 30mg pen is the flagship for multi-week titration protocols; the 20mg pen is suited to shorter studies where upfront cost is the primary constraint. Both are Janoshik-verified, dispatched cold-chain, and supplied strictly for in-vitro laboratory research.
| Feature | Retatrutide 30mg Pen | Retatrutide 20mg Pen |
|---|---|---|
| Format | Prefilled Pen | Prefilled Pen |
| Total Content | 30mg | 20mg |
| Clicks | 300 (0.1mg/click) | 200 (0.1mg/click) |
| Purity | 99.262% HPLC | 99.841% HPLC |
| Lab Verification | Janoshik Analytical | Janoshik Analytical |
| Batch | RETP002 | RET-20-C-2604-001 |
| Price (1 pen) | AED 1,800 | AED 1,200 |
| Price (5+ pack) | AED 1,500/pen | AED 1,000/pen |
| Dubai Delivery | Same day | Same day |
Understanding the regulatory framework is essential before sourcing any research compound in the UAE. Retatrutide occupies a specific position within this framework that researchers should be aware of.
Under MoHAP Circular 17/2022, research-grade peptides that are clearly labelled for in-vitro laboratory use and are not marketed for human consumption operate within the existing regulatory framework. Retatrutide is not classified as a controlled substance in any UAE jurisdiction. As an investigational compound without regulatory approval from the FDA or any other authority, it falls outside the scope of scheduled pharmaceutical regulations.
This is distinct from approved prescription GLP-1 medications like semaglutide (Ozempic/Wegovy) or tirzepatide (Mounjaro), which are regulated pharmaceuticals available only through licensed pharmacies with a prescription. Retatrutide will not be available through clinical channels until after FDA approval and subsequent MoHAP regulatory review.
The requirement is that all materials carry “For Research Use Only” labelling and that no therapeutic claims are made. For a broader overview of peptide legality across jurisdictions, see our peptide legality guide, our Dubai-specific legality brief, our peptides in the UAE overview, and the UAE, GCC and Lebanon guide hub if the search has regional intent beyond Dubai.
If you need the molecule-level routing layer before screening suppliers, open the Retatrutide Research Hub. It separates mechanism, approval status, dosing, Dubai availability, and trial milestones so this checklist can stay focused on proof and supplier quality.
Not all peptide suppliers maintain equivalent quality standards. The following criteria separate verified research-grade sources from unreliable ones. Applying this checklist before placing any order protects both research integrity and laboratory budgets.
The single most important indicator of a legitimate supplier is independent purity verification. Demand HPLC (High-Performance Liquid Chromatography) analysis conducted by a third-party laboratory — not an in-house test. A minimum threshold of 99% purity is standard for research-grade retatrutide. Remy Peptides uses Janoshik Analytical, an independent Czech laboratory widely recognised in the peptide research community, and publishes full test results for each released Retatrutide batch.
A genuine COA is batch-specific, dated, and includes quantitative HPLC data with retention times and peak area percentages. Generic specification sheets or undated documents are insufficient. Every Remy Peptides batch COA is published at /coa/ with the batch number, test date, and complete analytical results. Batch RETP002 is verified at 99.262% purity. For a field-by-field reading of HPLC purity, assay, LC-MS identity, endotoxin, TFA, and heavy metals, use the Peptide COA Guide.
Retatrutide is available in three formats: prefilled pen, lyophilised powder vial, and raw powder. For laboratory research requiring precise dosing, prefilled pens eliminate reconstitution errors and contamination risk. In Dubai’s climate — where summer temperatures regularly exceed 45°C — cold-chain delivery is not optional. Insulated, temperature-monitored packaging is essential to preserve peptide integrity from dispatch to laboratory receipt. For a complete breakdown of pen mechanics and dosing protocols, see our retatrutide pen guide.
Reputable suppliers publish pricing in local currency (AED) without hidden fees for shipping, cold-chain packaging, or COA documentation. Volume discounts should be clearly tiered. Any supplier that cannot provide upfront pricing or requires negotiation before revealing costs warrants caution.
Format selection directly impacts dosing accuracy, contamination risk, and workflow efficiency in the laboratory. The following comparison covers the key variables researchers should evaluate.
| Criterion | Prefilled Pen | Lyophilised Vial |
|---|---|---|
| Format | Ready-to-use Pen | Powder requiring reconstitution |
| Dosing Precision | 0.1mg per click (mechanical) | Volumetric (syringe-dependent) |
| Contamination Risk | Minimal (sealed system) | Higher (reconstitution step) |
| Storage Stability | High (factory-sealed) | Moderate (post-reconstitution) |
| Preparation Time | None | 5–10 minutes per vial |
| Cost per mg (30mg) | AED 60/mg (single) — AED 50/mg (5+ pack) | Varies widely by source |
For most Dubai-based research protocols, the prefilled pen format offers superior dosing reproducibility and eliminates the primary contamination vector associated with powder reconstitution. The sealed pen system also provides better thermal stability during last-mile delivery — a significant consideration in the UAE climate.
For detailed guidance on pen mechanics and click-based titration, see our retatrutide pen guide. For storage protocols across all formats, see our peptide stability and storage guide.
The key differentiator for retatrutide is its triple-receptor mechanism. Approved GLP-1 therapies and next-generation compounds vary in the number of metabolic receptors they engage, which directly correlates with observed efficacy in published trials.
The addition of glucagon receptor agonism is the trial-reported driver of incremental efficacy over dual-agonist compounds. For a full breakdown including dosing schedules and mechanism analysis, see our Retatrutide vs Tirzepatide vs CagriSema comparison.
Remy Peptides publishes transparent AED pricing across three volume tiers for the 30mg prefilled Pen:
Volume-tier pricing at Remy Peptides reduces the effective per-milligram cost on the 30mg pen — AED 1,800 (AED 60/mg) for a single pen, AED 3,300 (AED 55/mg) at the 2-pack tier, and AED 7,500 (AED 50/mg) at the 5+ tier. This provides verified cost-per-milligram transparency for HPLC-tested retatrutide in the UAE market.
Red flag: Prices significantly below AED 1,400 per 30mg pen should trigger due diligence. Sub-market pricing typically indicates compromised purity, lack of third-party testing, or substituted compounds. Always request a batch-specific COA before purchasing from any supplier.
View current pricing and availability at our Dubai price and delivery guide or move into the checkout flow from there when you are ready.
For laboratories running multi-week protocols, the total cost per milligram is often more relevant than the per-pen price. Volume tiers reduce the effective per-mg figure rather than just the unit price, which matters once a study spans multiple titration steps.
The volume-tier structure is designed to support sustained research protocols — particularly the 24-week and 48-week titration schedules modelled on the TRIUMPH clinical trial design — without requiring repeated single-unit procurement at premium rates.
All retatrutide orders dispatch from the Remy Peptides Dubai facility in insulated cold-chain packaging. Delivery windows vary by emirate, with Dubai offering same-day arrival when the order is confirmed before the cutoff.
Insulated, temperature-monitored packaging is critical when UAE summer ambient temperatures exceed 45°C. Cold-chain integrity from dispatch to laboratory receipt is the documented Remy Peptides standard regardless of order size or destination emirate.
Once a supplier passes the screen above, a research procurement workflow stays compliance-first. The sequence below is structured around verification rather than transaction speed.
Material is supplied strictly for in-vitro laboratory research. For a single consolidated view of Retatrutide UAE supply across all emirates, use the UAE supply reference.
This guide draws on clinical data from Eli Lilly’s TRIUMPH trial programme, published Phase 2 results in the New England Journal of Medicine, Janoshik Analytical test reports for Remy Peptides batch RETP002, and UAE regulatory documents including MoHAP Circular 17/2022. All supplier evaluation criteria are based on analytical chemistry standards and peptide stability research. Read our editorial policy →